ImmunityBio

Class action lawsuit filed against $IBRX alleging securities fraud over false statements regarding Anktiva capabilities. Investors who purchased shares January-March 2026 may be eligible.

ImmunityBio faces class action securities fraud lawsuit over allegedly false Anktiva drug claims. Schall Law Firm recruiting investors who purchased stock January-March 2026.

ImmunityBio investors must act by May 26, 2026 to claim lead plaintiff status in securities fraud class action alleging executive misstatements about Anktiva drug capabilities.

Class action lawsuit filed against $IBRX over alleged misleading statements regarding Anktiva capabilities between January-March 2026. Lead plaintiff deadline May 26.

Rosen Law Firm urges ImmunityBio investors with $100K+ losses to pursue claims by May 26 deadline in class action alleging material misstatements about Anktiva capabilities.

ImmunityBio ($IBRX) investors face May 26, 2026 deadline to claim lead plaintiff status in securities lawsuit alleging false statements about Anktiva capabilities and business prospects.

ImmunityBio investors have until May 26, 2026, to join securities fraud class action over allegedly false Anktiva claims.

Portnoy Law Firm launches class action against $IMNB following failed Phase 2 glioblastoma trial, citing investor losses from steep stock decline.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust ($FBRT) over alleged misstatements on dividends; April 2026 deadline for lead plaintiff participation.

Rosen Law Firm urges $IBRX investors to join securities lawsuit alleging false statements about Anktiva capabilities. May 26, 2026 deadline looms for class action participation.

Schall Law Firm launches class action lawsuit against ImmunityBio for alleged securities fraud over false Anktiva drug statements between January-March 2026.

ImmunityBio stock rallied 7% after reporting $44.2M in Q1 product revenue, up 168% YoY, despite FDA warning over Anktiva marketing claims.

Rosen Law Firm files securities class action against Snowflake alleging executives concealed material information about product efficiency and pricing changes affecting consumption and revenues.

Class action lawsuit filed against Pinterest for allegedly making false statements about advertising revenues and tariff impacts. Stock plunged 16.8% after Q4 results missed expectations.

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.